354 related articles for article (PubMed ID: 27060025)
1. O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression.
Zhu G; Tao T; Zhang D; Liu X; Qiu H; Han L; Xu Z; Xiao Y; Cheng C; Shen A
Glycobiology; 2016 Aug; 26(8):820-833. PubMed ID: 27060025
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAcylation promotes the migratory ability of hepatocellular carcinoma cells via regulating FOXA2 stability and transcriptional activity.
Huang H; Wu Q; Guo X; Huang T; Xie X; Wang L; Liu Y; Shi L; Li W; Zhang J; Liu Y
J Cell Physiol; 2021 Nov; 236(11):7491-7503. PubMed ID: 33843053
[TBL] [Abstract][Full Text] [Related]
3. O-GlcNAc transferase activates stem-like cell potential in hepatocarcinoma through O-GlcNAcylation of eukaryotic initiation factor 4E.
Cao B; Duan M; Xing Y; Liu C; Yang F; Li Y; Yang T; Wei Y; Gao Q; Jiang J
J Cell Mol Med; 2019 Apr; 23(4):2384-2398. PubMed ID: 30677218
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of OGT by Caveolin-1 promotes hepatocellular carcinoma cell migration and invasion.
Wang L; Feng Y; Zhang C; Chen X; Huang H; Li W; Zhang J; Liu Y
Cell Biol Int; 2021 Nov; 45(11):2251-2263. PubMed ID: 34288245
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation.
Zhu Q; Zhou L; Yang Z; Lai M; Xie H; Wu L; Xing C; Zhang F; Zheng S
Med Oncol; 2012 Jun; 29(2):985-93. PubMed ID: 21461968
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
7. Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells.
Lai CY; Liu H; Tin KX; Huang Y; Yeh KH; Peng HW; Chen HD; He JY; Chiang YJ; Liu CS; Weng SY; Tao MH; Yen JJ; Yang-Yen HF
Oncogene; 2019 Jan; 38(3):317-331. PubMed ID: 30097606
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
9. O-GlcNAcylation of SIX1 enhances its stability and promotes Hepatocellular Carcinoma Proliferation.
Chu Y; Jiang M; Wu N; Xu B; Li W; Liu H; Su S; Shi Y; Liu H; Gao X; Fu X; Chen D; Li X; Wang W; Liang J; Nie Y; Fan D
Theranostics; 2020; 10(21):9830-9842. PubMed ID: 32863962
[TBL] [Abstract][Full Text] [Related]
10. Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition.
Shan X; Jiang R; Gou D; Xiang J; Zhou P; Xia J; Wang K; Huang A; Tang N; Huang L
FEBS J; 2023 Sep; 290(18):4543-4561. PubMed ID: 37247228
[TBL] [Abstract][Full Text] [Related]
11. Undetectable histone O-GlcNAcylation in mammalian cells.
Gagnon J; Daou S; Zamorano N; Iannantuono NV; Hammond-Martel I; Mashtalir N; Bonneil E; Wurtele H; Thibault P; Affar el B
Epigenetics; 2015; 10(8):677-91. PubMed ID: 26075789
[TBL] [Abstract][Full Text] [Related]
12. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
[TBL] [Abstract][Full Text] [Related]
13. HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
Xie HJ; Noh JH; Kim JK; Jung KH; Eun JW; Bae HJ; Kim MG; Chang YG; Lee JY; Park H; Nam SW
PLoS One; 2012; 7(4):e34265. PubMed ID: 22496786
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcylation of RAB10 promotes hepatocellular carcinoma progression.
Lv Z; Ma G; Zhong Z; Xie X; Li B; Long D
Carcinogenesis; 2023 Dec; 44(10-11):785-794. PubMed ID: 37218374
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
Buurman R; Sandbothe M; Schlegelberger B; Skawran B
Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
[TBL] [Abstract][Full Text] [Related]
16. Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling.
Jiang M; Qiu Z; Zhang S; Fan X; Cai X; Xu B; Li X; Zhou J; Zhang X; Chu Y; Wang W; Liang J; Horvath T; Yang X; Wu K; Nie Y; Fan D
Oncotarget; 2016 Sep; 7(38):61390-61402. PubMed ID: 27542217
[TBL] [Abstract][Full Text] [Related]
17. Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263.
Wang L; Li G; Zhou Z; Ge C; Chen Q; Liu Y; Zhang N; Zhang K; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Oncogene; 2023 Jul; 42(30):2329-2346. PubMed ID: 37353617
[TBL] [Abstract][Full Text] [Related]
18. Decreasing O-GlcNAcylation affects the malignant transformation of MCF-7 cells via Hsp27 expression and its O-GlcNAc modification.
Netsirisawan P; Chaiyawat P; Chokchaichamnankit D; Lirdprapamongkol K; Srisomsap C; Svasti J; Champattanachai V
Oncol Rep; 2018 Oct; 40(4):2193-2205. PubMed ID: 30106436
[TBL] [Abstract][Full Text] [Related]
19. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis.
Liu R; Gou D; Xiang J; Pan X; Gao Q; Zhou P; Liu Y; Hu J; Wang K; Tang N
Oncogene; 2021 Dec; 40(50):6707-6719. PubMed ID: 34650217
[TBL] [Abstract][Full Text] [Related]
20. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation.
Xiang J; Chen C; Liu R; Gou D; Chang L; Deng H; Gao Q; Zhang W; Tuo L; Pan X; Liang L; Xia J; Huang L; Yao K; Wang B; Hu Z; Huang A; Wang K; Tang N
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
